A. C. via Unsplash+Belgian Coultreon Biopharma has raised US$125m in a big‑pharma‑backed Series A round to push its first‑in‑class SIK3 inhibitor into Phase II after an ongoing Phase I programme in autoimmune disease
ADVERTISEMENT
Belgian Coultreon Biopharma has raised US$125m in a big‑pharma‑backed Series A round to push its first‑in‑class SIK3 inhibitor into Phase II after an ongoing Phase I programme in autoimmune disease